Overview

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label non-randomized study in subjects with advanced or metastatic solid tumors who are no longer responding to available therapy. HALAVEN will be administered to subjects on Days 1 and 8 of a 21-day cycle.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.